BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 32856864)

  • 21. Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group.
    Cavalli F; Ceriani L; Zucca E
    Am Soc Clin Oncol Educ Book; 2016; 35():e368-75. PubMed ID: 27249743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interim FDG-PET/CT for Response Assessment of Lymphoma.
    Zeman MN; Akin EA; Merryman RW; Jacene HA
    Semin Nucl Med; 2023 May; 53(3):371-388. PubMed ID: 36376131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols.
    Zaman MU; Fatima N; Zaman A; Zaman U; Zaman S; Tahseen R
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2343-2348. PubMed ID: 32856864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
    Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma.
    Wang R; Xu B; Liu C; Guan Z; Zhang J; Li F; Sun L; Zhu H
    Br J Radiol; 2018 Nov; 91(1091):20180240. PubMed ID: 30004787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of Dmax and %ΔSUVmax of
    Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
    BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
    Gupta N; Singh N
    Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
    de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
    Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV
    Rekowski J; Hüttmann A; Schmitz C; Müller SP; Kurch L; Kotzerke J; Franzius C; Weckesser M; Bengel FM; Freesmeyer M; Hertel A; Krohn T; Holzinger J; Brink I; Haberkorn U; Nyuyki F; van Assema DME; Geworski L; Hasenclever D; Jöckel KH; Dührsen U
    J Nucl Med; 2021 Jan; 62(1):37-42. PubMed ID: 32385164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Kitajima K; Okada M; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Tamaki H; Fujimori Y; Ueda S; Kawamoto H; Taniguchi J; Yamakado K
    Oncotarget; 2019 Sep; 10(52):5403-5411. PubMed ID: 31534626
    [No Abstract]   [Full Text] [Related]  

  • 31. Predictors of metabolic response in propensity-matched lymphoma patients on interim
    Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R; Zaman S
    World J Nucl Med; 2019; 18(2):154-159. PubMed ID: 31040747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic analysis of interim
    Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Burggraaff CN; de Jong A; Hoekstra OS; Hoetjes NJ; Nievelstein RAJ; Jansma EP; Heymans MW; de Vet HCW; Zijlstra JM
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):65-79. PubMed ID: 30141066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
    Dührsen U; Müller S; Hertenstein B; Thomssen H; Kotzerke J; Mesters R; Berdel WE; Franzius C; Kroschinsky F; Weckesser M; Kofahl-Krause D; Bengel FM; Dürig J; Matschke J; Schmitz C; Pöppel T; Ose C; Brinkmann M; La Rosée P; Freesmeyer M; Hertel A; Höffkes HG; Behringer D; Prange-Krex G; Wilop S; Krohn T; Holzinger J; Griesshammer M; Giagounidis A; Raghavachar A; Maschmeyer G; Brink I; Bernhard H; Haberkorn U; Gaska T; Kurch L; van Assema DME; Klapper W; Hoelzer D; Geworski L; Jöckel KH; Scherag A; Bockisch A; Rekowski J; Hüttmann A;
    J Clin Oncol; 2018 Jul; 36(20):2024-2034. PubMed ID: 29750632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
    Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
    J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interim FDG-PET Imaging in Lymphoma.
    Gallamini A; Zwarthoed C
    Semin Nucl Med; 2018 Jan; 48(1):17-27. PubMed ID: 29195613
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.